

# **MMed Thesis Presentation**

Dr. Andree Zamunu  
MMed II candidate 2021

**Peripheral intravenous cannula complications in children admitted to Port Moresby General Hospital: a prospective, observational study.**



# Introduction

- Insertion of peripheral intravenous cannulas (PIVCs) is one of the most common procedures performed in hospitalised patients.
- More than 80% of patients undergo this procedure.
- PIVCs are inserted for several reasons
- Complications can arise from PIVC use, of which phlebitis is the most common

- Risk factors for PIVC complications include
  - Use of drugs that have vesicant or pro-thrombotic properties
  - the number of PIVC used
  - the duration of intravenous (IV) treatment;
  - PIVC gauge;
  - inadequate dressing
  - insertion site at the antecubital fossa;

To our knowledge, there are no published studies on the complications of PIVCs in children in Papua New Guinea.

# **Aim**

To determine the type and frequency of complications associated with PIVC use in children admitted to Port Moresby General Hospital (PMGH).

# Methodology

## Study design

- This was a prospective, observational study.

## Study Site

- Paediatric department of the PMGH

## Study duration

- Data collection period: 2/6/2020 – 30/10/2020

## Population and Sample size

- The study population comprised all admitted paediatric patients who met the inclusion criteria. 104 patients were recruited for the study.

## *Inclusion criteria*

- All children from eight days old to thirteen years old who were admitted to the general paediatric wards.

## *Exclusion criteria*

- Referred patients with an existing PIVC in situ,
- Patients who had had IV treatment at CED for >24 hours before admission, and
- Neonates admitted to the special care nursery (SCN)

## **Recruitment and Data collection**

- Convenient sampling was used to recruit the patients.
- A structured data collection form was used to gather the data.
- Patients were followed up daily until discharged, or until their PIVCs were removed.
  - Each PIVC site was inspected for swelling, redness, necrosis and leaking; the PIVC site was also palpated for pain.

## **Safety considerations within the study**

- All PIVCs that developed a complication and were noted by the primary researcher during daily follow up were removed.



## Outcomes


- Primary outcome: the incidence of complications associated with PIVC use.
- Secondary outcome: identify risk factors for developing a PIVC complication.

## Data Analysis

- The data were analysed using Epi Info version 7.
- Percentages and absolute frequency were calculated for categorical data.
- For quantitative data, the mean and standard deviation were calculated.
- Odds Ratios, 95% CI and  $p$ -values were calculated using Open Epi.
- A  $p$  value  $<0.05$  was considered significant.

# Results

Figure 1. Patient flow during study period



**Table 1.** Age and gender distribution of study participants. n = 104.

	<b>n</b>	<b>(%)</b>
<b>Sex</b>		
Male	53	51
Female	51	49
<b>Age</b>		
< 29 days	10	10
29 days – 1 year	50	48
> 1 year – 5 years	27	26
>5 years	17	16
Range	0.02 – 12.58	

**Table 2. Diagnosis and number of co-morbidities of study participants**

<b>Diagnosis (n = 194)</b>	<b>n</b>	<b>%</b>
Malnutrition	33	17
Acute lower respiratory tract infection	24	12
Acute gastroenteritis	20	10
Tuberculosis	15	8
Human immunodeficiency virus infection	12	6
Neonatal sepsis	11	6
Dehydration	10	5
Acute bacterial meningitis	9	5
Skin infections	8	4
Anaemia	7	4
Congenital heart disease	7	4
Persistent gastroenteritis	7	4
Electrolyte imbalance	4	2
Cerebral palsy	3	2
Sepsis	3	2
Others	21	10.5
<b>Number of co-morbidities (n =104)</b>		
0	47	45
1	34	33
≥2	23	22



PEEL OPEN  
**PLUSFLON™**  
 I.V. CANNULA  
 with injection valve with wings.  
 PTFE Radio-Opaque

- I.V. Cannula
- Infusionskanyl
- Canula IV
- IV kanyle
- I.V. Canula
- Venerverweil -kanüle
- Canula I.V.
- I.V. Kanyle
- IV-kanyyli
- I.V.Kanül
- Catheter court IV
- Cannula EV
- Kaniula Dozylna

A PRODUCT OF  
 The Mediplus Company  
 Mfd. By:-  
 Mediplus (India) Limited  
 1261-1262, M.I.E., Part-E,  
 Bahadurgarh - 124 507,  
 HARYANA (INDIA) 21NA  
 Customer Care No.:  
 011- 27353189, 49046544  
 MW/175 Rev.10

CE 0120  
 STERILE EO  
 MADE IN INDIA  
 M.L. No.: MFG/MD/2018/000069  
 REF: 1732011101  
 LOT: 91286/575  
 Size: 20 G  
 Ø x L: 1.1x32mm  
 Flow: 60ml/min.  
 Mfg: 2020-01  
 Exp: 2024-12  
 M.L.P. No.: 1204-First of its kind


**Table 3.** Characteristics of inserted PIVCs, sites of insertion, type of plaster used, PIVC lifespan and PIVC outcome.

<b>PIVCs inserted</b>	<b>n</b>	<b>(%)</b>
Total	330	
Mean (SD)	3.17±1.89	
Range	1 - 11	
<b>PVC Gauge</b>		
20 FG (pink)	2	1
22 FG (blue)	112	35
24 FG (yellow)	164	50
26 FG (purple)	52	16
<b>Site of insertion</b>		
Dorsum of foot	33	10
Ankle	46	14
Dorsum of hand	32	10
Wrist	176	53
Forearm	16	5
Antecubital fossa	20	6
Others	7	2
<b>Plaster used to secure PIVC</b>		
AcoPore with reinforced gauze bandage	0	0
AcoPore without reinforced gauze bandage	22	7
Leukoplast with reinforced gauze bandage	5	1
Leukoplast without reinforced gauze bandage	240	73
Mediplast with reinforced gauze bandage	4	1
Mediplast without reinforced gauze bandage	27	8
Tensoplast with reinforced gauze bandage	0	0
Tensoplast without reinforced gauze bandage	32	10

Table 3... Continued

	n	(%)
<b>PIVC lifespan (days)</b>		
0	38	11
1	119	36
2	111	34
3	36	11
4	16	5
≥5	10	3
Mean	1.72	
Range	0 – 7	
<b>PIVC outcome</b>		
Developed complication	222	67
No complication	108	33

Figure 2. Outcomes of the 330 PIVCs. Numbers in brackets are percentages.





## Risk factors for developing a PIVC complication

- Patients were more likely to develop complications with a larger gauge PIVC
- Compared to size 24 FG PIVC, children with size 22 FG PIVC were 2.06 times more likely to develop a complication (95% CI: 1.20 – 3.60;  $p = 0.012$ )
- Patients were 2.55 times more likely to develop a complication with a size 22 FG PIVC compared to a size 26 FG (95% CI: 1.24 – 5.19;  $p = 0.016$ )
- Regarding clinical complications, children with size 22 FG PIVCs were 3.26 times more likely to develop one compared to size 26 FG PIVC ([79/33 vs. 22/30 (95% CI:1.64 – 6.50;  $p = 0.0007$ )].

# Discussion

- The incidence of complications per patient with one or more PIVCs was 83%.
  - Approximately 2.5 times higher than the 34% found by a recent systematic review and meta-analysis of 32 studies done on paediatric patients <sup>(12)</sup>.
- Similarly, the incidence of complications per PIVC inserted was higher (67%) compared to other studies on paediatric populations which reported incidences of 16% - 51.9% <sup>(4,7,8,13-15)</sup>.

# Clinical complications

- Infiltration
  - comprised 60% of the complications. This was higher compared to the 10% - 32.7% found in 6 other studies (7,8,12,14,15,17).
- Phlebitis
  - Second most common with 29%. This was lower than the 71.25% found by Nagpal *et al* (21), but higher than the incidence found in five other studies on paediatric patients (6-8,12,17).
  - The incidence is approximately 6 times higher than the Infusion Nurse Society's recommended benchmark rate of no more than 5% (22).
- Skin necrosis.
  - Two cases
  - Ben Abdelaziz *et al* noted one case of skin necrosis (7).
  - Other studies did not mention it as a complication of PIVC use (8,13-15).

# Mechanical Complications

- Obstruction
  - Commonest complication, with an incidence of 6%. Indarwati *et al* also noted a 6% incidence of PIVC obstruction <sup>(12)</sup>.
  - Four other studies reported incidences of obstruction greater than the one we found (4,8,14,15).
- Leaking
  - made up 4% of the complications
  - Only one other study reported leaking as a PIVC complication <sup>(12)</sup>.

# Factors contributing to PIVC complications

- Only significant factor: PIVC gauge; the bigger the PIVC gauge the greater the risk.
- Non-significant factors included:
  - Age
  - Gender
  - Undernourishment
  - PIVC insertion site
  - IV infusion method, IV fluid type and IV fluid rate
  - Number of drugs administered
  - PIVC indwell time,
  - combined administration of both IV fluids and drugs
  - Number of PIVCs inserted

- There was no documentation of
  - Time of PIVC insertion
  - Site of initial insertion
  - Time of PIVC removal
  - Reason for removal of initial PIVC
  - Number of attempts at reinsertion
  - Site of reinsertion

# Limitations

1. Missing data from the patients' charts.
2. Primary researcher was ill during data collection.
3. COVID-19 pandemic affected patient recruitment.
4. Post-PIVC removal phlebitis could not be determined as patients were not followed up post PIVC removal
5. PIVCs were inserted by different cadres of health workers. This might affect PIVC lifespan and development of complications.
6. There were patients admitted during the study period who had PIVC complications that were not included in the study due to convenient sampling being used to recruit patients. The complication rate would have been much higher had they been included.

# Conclusion

- The incidence of PIVC complications in the paediatric department of PMGH is high.
- Large PIVC gauge is a significant risk factor for developing complications.
- It is the responsibility of the clinical team to ensure that the PIVC is working well, to observe it closely for the development of complications, and to ensure it is not left in situ unnecessarily.



# Acknowledgement

I would like to sincerely thank and acknowledge the following people for their invaluable contributions:

- My God – the source of everything
- Professor Trevor Duke - Royal Children's Hospital Melbourne, Melbourne University
- Dr. Francis Pulsan – Lecturer Child Health, School of Medicine & Health Sciences, University of Papua New Guinea
- Professor John D. Vince – Deputy Dean, School of Medicine & Health Sciences, University of Papua New Guinea
- All the patients and their parents who participated in the survey
- Sister. Martha Rapea – Sister-in-Charge, ward 1C, Port Moresby General Hospital
- Paediatric Team – Port Moresby General Hospital
- The management of Port Moresby General Hospital

# References

1. *Intravenous therapy.* C Waitt, P Waitt, M Pirmohamed. 03 February 2004, Postgraduate Medical Journal, Vol. 80, pp. 1 - 6.
2. *How to inset a peripheral venous cannula.* Datta, Samyadev. 1990, Br J Hosp Med, Vol. 43, pp. 67-9.
3. *Incidence, severity and risk factors of peripheral intravenouscannula-induced complications: An observational prospective study.* Simin D, Milutinovic D, Turkulov V, Brkic S. May 2019, Journal of Clinical Nursing, pp. 1585 - 1599.
4. *Incidence of local complications and risk factors associated with peripheral intravenous catheter in neonates.* Danski MTR, Minogrance P, Johann DA, Vayego SA, Lind J. 1, 2016, Vol. 50, pp. 22 - 28.
5. *Prospective study of incidence and predictors of peripheral intravenous catheter-induced complications.* Abolfotouh MA, Salam M, Bani-Mustafa A, White D, Balkhy H. Riyadh : Dove Press, 8 December 2014, Therapeutics and Clinical Risk Management, Vol. 10.
6. *Adverse events related to the use of peripheral intravenous catheter in children according to dressing regimen.* Machado AF, Pedeira MLG, Chaud MN. 3, Sao Paulo : s.n., May 2008, Revista Latino-Americana de Enfermagem , Vol. 16, pp. 362 - 367.
7. *Peripheral venous catheter complications in children: predisposing factors in a multicentre prospective cohort study.* Ben Abdelaziz R, Hafsi H, Hajji H, Boudabous H, Chehida AB, Mrabet A, Boussetta K, Barsoui S, Sammond A, Hamzaoui M, Azzouz H, Tebib N. 208, 2017, BMC Pediatrics, Vol. 17.
8. *Peripheral intravenous catheter duration and failure in pediatric acute care: a prospective cohort study.* Malyon L, Ullman AJ, Phillips N, Young J, Kleidon T, Murfield J, Rickard CM. 6, s.l. : Wiley Online Library, 2014, Emergency Medicine Australasia, Vol. 26. <https://doi.org/10.1111/1742-6723.12305>.
9. *Peripheral venous catheter-related adverse events: evaluation from a multicentre epidemiological study inFrance (the CATHEVAL project).* Miliani K, Thillard D, Chauvin V, Martin E, Astagneau P and group, CATHEVAL study. 1, 3 January 2017, PLoS ONE, Vol. 12, pp. 1 - 17.
10. *Phlebitisand infiltration: vascular trauma associated with the peipheral venous catheter.* Braga LM, Parreira PM, Oliveira ASS, Monico LSM, Arreguy-Sena C, Henriques MA. 2018, Revista Latino-Americana de Enfermagem, Vol. 26.

11. *The incidence of thrombophlebitis following the use of peripheral intravenous cannula in post-operative patients: a prospective observational study.* Saji J, Korula SV, Matthew A, Mohan L. 6, June 2015, ISOR Journal of Dental and Medical Sciences, Vol. 1, pp. 1 - 4.
12. *Incidence of peripheral intravenous catheter failure and complications in paediatric patients: systematic review and meta analysis.* Indarwati F, Matthew S, Munday J, Keogh S. s.l. : Elsevier Ltd, February 2020, International Journal of Nursing Studies, Vol. 102. 10.1016/j.ijnurstu.2019.103488.
13. *Predisposing factors for infiltration in children submitted to peripheral venous catheterization.* Jacinto AKL, Avelar AFM, Pedreira MLG. 6, November-December 2011, Journal of Infusion Nursing, Vol. 34, pp. 391 - 398. doi: 10.1097 / NAN.0b013e3182306491.
14. *Peripheral intravenous catheter problems in infants and children presenting for anesthesia and surgery.* Tripi PA, Thomas S, Clebone A, Goldfinger MM and Tobias JD. 4, February 2016, Middle East Journal of Anaesthesiology, Vol. 23, pp. 411 - 414. PMID:27382809.
15. *Risk factors for site complications of intravenous therapy in children and adolescents with cancer.* Santos LM, Silva CSG, Machado ES, Almeida AHV, Silva BSM and Avelar AFM. 4, Feira de Santana : s.n., 12 May 2020, Revista Brasileira de Enfermagem, Vol. 73. <https://doi.org/10.1590/0034-7167-2019-0471>.
16. *Incidence of local complications in peripheral venous catheters and associated risk factors.* Danski MTR, Oliveira GLR, Johann DJ, Pedrolo E and Vayego SA. 6, 2015, Acta Paulista Enfermagem, Vol. 28, pp. 517 - 523. <http://dx.doi.org/10.1590/1982-0194201500087>.
17. *Dwell time of peripheral intravenous catheter and its association with the risk of infiltration, phlebitis, and pain in pediatric patients.* Chan C, Leung S, Ho S, Choi K, Ip W. 4, Hong Kong : PlumX Metrics, 1 April 2012, The Journal of Pain, Vol. 13. <https://doi.org/10.1016/j.pain.2012.01.030>.
18. *Peripheral intravenous catheter (PIVC) related local complications among patients in KFCH-Jizan.* Makafi SA, Marfega MACM. 3, Jizan : s.n., 2 August 2017, Journal of Advanced Practices in Nursing, Vol. 2. doi:10.4172/2573-0347.1000138.
19. *The development of phlebitis and infiltration in patients with peripheral intravenous catheters in the neurosurgery clinic and affecting factors.* Erdogan BC, Denat Y. 2, Ankara : s.n., May - August 2016, International Journal of Caring Sciences , Vol. 9, pp. 619 - 629 .
20. *Risk factors for complications in peripheral intravenous catheters in adults: secondary analysis of a randomised controlled trial.* Johann DA, Danski MTR, Vayego SA, Barbosa DA, Lind J. e2833, 2016, Revista Latino-Americana de Enfermagem, Vol. 24. DOI: <http://dx.doi.org/10.1590/1518-8345.1457.2833>.

21. *A study assess the clinical pattern of phlebitis among children admitted in selected hospital of Ambala, Haryana.* Nagpal P, Khera GK and Kumar Y. 2, New Delhi : s.n., April 2015, Nursing and Midwifery Research Journal, Vol. 11.
22. *Phlebitis.* LA, Gorski. 1, s.l. : Infusion Nurses Society, September - October 2006, Journal of Infusion Nursing, Vol. 29, pp. 58 - 59.
23. *Incidence of Phlebitis associated with the use of peripheral IV catheter and following catheter removal.* Urbanetto JS, Peixoto CG, May TA. Porto Alegre : s.n., 2016, Revista Latino-Americana de Enfermagem, Vol. 24. DOI: <http://dx.doi.org/10.1590/1518-8345.0604.2746>.
24. *Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial .* Webster J, Clarke S, Paterson D, van Dyk S, Gale C, Hopkins T. a339, 08 July 2008, BMJ, Vol. 337. doi:10.1136/bmj.a339.
25. *Prevalence of phlebitis in adult patients with peripheral venous catheter.* Urbanetto JS, Rodrigues AB, Oliveira DJ, Dornelles FF, Filho JMR, Gustavo AS, Schilling MCL. 3, 2011, Revista De Enfermagem Da UFSM, Vol. 1. DOI: <https://doi.org/10.5902/217976923283>.
26. *Study on incidence of phlebitis following the use of peripheral intravenous catheter.* Mandal A, Raghu K. 9, Kalaikunda : s.n., 30 September 2019, Journal of Family Medicine and Primary Care, Vol. 8, pp. 2827 - 2831. PMC6820419.
27. *A model of phlebitis associated with peripheral intravenous catheters in orthopedic inpatients.* Lee S, Kim K, Kim JS. 16, Seoul : s.n., 14 September 2019, International Journal of Environmental Research and Public Health, Vol. 3412. doi:10.3390/ijerph16183412.
28. *Catheter indwell time and phlebitis development during peripheral intravenous catheter administration.* Pasalioglu KB, Kaya H. 4, 2014, Pakistan Journal of Medical Science , Vol. 30, pp. 725 - 730. doi: <http://dx.doi.org/10.12669/pjms.304.5067>.
29. *Assessment of risk factors of phlebitis amongst intravenous cannulated patients.* Thakur R, Kaur P, Kaur S, Bhalla A. 3, Chandigarh : s.n., 106 - 114 January 2011, Iranian Journal of Nursing and Midwifery Research, Vol. 7. <http://doi.org/10.33698/NRF0129> .
30. *Peripheral intravenous catheter related phlebitis and its contributing factors among adult population at KU Teaching Hospital.* Singh R, Bhandary S, Pun KD. 24, Kathmandu : s.n., October - December 2008, Kathmandu University Medical Journal , Vol. 6, pp. 443 - 447. doi: 10.3126/kumj.v6i4.1732.

31. *Risk factors for peripheral intravenous catheter failure: a multivariate analysis of data from a randomised controlled trial.* Wallis MC, McGrail M, Webster J, Marsh N, Gowardman J, Playford EG, Rickad CM. 1, January 2014, Infection Control and Hospital Epidemiology, Vol. 35, pp. 63 - 68. PMID: 24334800.
32. *The epidemiology of peripheral vein thrombosis: a critical review.* Tagalakis V, Khan SR, Libman M, Blostein M. 2, s.l. : Pubmed, 1 August 2002, The American Journal of Medicine, Vol. 113, pp. 146 - 151. PMID: 12133753.
33. *Position of peripheral venous cannulae and the incidence of thrombophlebitis: an observational study.* Cicolini G, Bonghi AP, Di Labio L, Di Mascio R. 6, s.l. : Pubmed, June 2009, Journal of Advanced Nursing, Vol. 65, pp. 1268 - 1273. PMID: 19374679.
34. *The effect of intravenous infiltration management program for hospitalized children.* Park SM, Jeong IS, Kim KL, Park KJ, Jung MJ, Jun SK. 2, s.l. : Elsevier Inc, 1 March 2016, Journal of Pediatric Nursing, Vol. 1, pp. 172 - 178. doi:<https://doi.org/10.1016/j.pedn.2015.10.013>.
35. *Avoiding the pitfalls of IV therapy. IV therapy: preventing complications.* Millam DA, Masoorly S. 15, 2009, The Nurse Friendly, Vol. 1, pp. 31 - 32.
36. *Intravenous cannulae: complications arising from their use and analysis of their predisposing factors.* Martinez JA, Fernandez P, Rodriguez E, Sobrino J, Torres M, Nubiola A, Buges J. 3, Barcelona : s.n., 18 June 1994, Medicina Clinica, Vol. 103, pp. 89 - 93.
37. *Peripheral intravenous cannulation: complication rates in the neonatal population: a multicentre observational study.* Legemaat M, Carr PJ, van Rens RM, van Dijk M, Poslawsky IE, van den Hoogen A. 4, 12 July 2016, The Journal of Vascular Access, Vol. 17, pp. 360 - 365.
38. ClinCal LLC. *ClinCalc.com*. [Online] 24 July 2020. [Cited: 25 September 2020.] <https://clincalc.com/stats/samplesize.aspx>.

# Thank you all

Any...

- Comments??
- Questions??
- Critiques??